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Diabetes mellitus and obesity are both related to the risk of cardiovascular disease and sudden death. In hypertensive guidelines,
diabetes and obesity, especially abdominal obesity, are regarded as high-risk factors. Ambulatory blood pressure monitoring
(ABPM)isanestablishedmethodforthemanagementofhypertension.However,ABPMisnotastandardtoolforthemanagement
of hypertension in diabetes and obesity. In this paper, recent data on the use of ABPM in diabetes and obesity will be discussed. In
patients with diabetes, the ambulatory BP level has been shown to be better than clinic BP in predicting cardiovascular events. A
riser pattern has been associated with increased risk of cardiovascular disease. White-coat hypertension and masked hypertension
in diabetics constitute a moderate risk. A nondipping pattern is very common in obese hypertensive patients. In this paper, we will
summarize the ﬁndings on the use of ABPM in patients with diabetes and obesity.
1.Introduction
There have been increasing numbers of diabetic and obese
patients in recent years. Hypertension coexisting with dia-
betes and obesity has a major impact on cardiovascular
prognosis. Patients with diabetes and obesity usually have
other risk factors, such as dyslipidemia, sleep apnea syn-
drome, and metabolic syndrome. Strict control of BP has
been recommended in these patients. The ACCORD trial
proved that aggressive BP control has no such beneﬁt on
cardiovascular prognosis in patients with diabetes [1], but a
new target level of BPin diabetes has not yet been established
in response to these ﬁndings. Therefore, individualized
control of BP is becoming more important in this post-
ACCORD era. In this paper, we summarized the data on
ABPM in diabetes and obesity.
2. Ambulatory Blood Pressure
MonitoringinDiabetes
Diabetes itself is classiﬁed as a high-risk factor for car-
diovascular disease, and when hypertension coexists with
diabetes, not only is the cardiovascular risk magniﬁed, but
cardiovascular target organ damages such as silent cerebral
infarcts (SCIs) and left ventricular hypertrophy (LVH) may
progress. This is why the target level of blood pressure
in diabetes is set as low as 130/80mmHg. In a seminal
paper by de la Sierra et al. based on ﬁndings from 42,947
patients included in the Spanish Society of Hypertension,
ABPM registry has shown that diabetes was associated with
nondipping status [2].
In clinical practice, it is sometimes very hard to identify
the true blood pressure level when the BP variability is very
large. In such cases, 24-hour BP monitoring (ABPM) is
useful for the assessment of the actual blood pressure level
and the prediction of cardiovascular prognosis. In patients
with diabetes, the guidelines of the International Diabetes
Federation (IDF) recommend that 24-hour ambulatory
monitoring (ABPM) be used if so-called white coat hyper-
tension is suspected, and it is limited in case of suspected
white-coat hypertension [3]. On the other hand, there are no
recommendationsinregardtoABPMintheguidelinesofthe
Japanese Society of Hypertension [4] or the American Dia-
betes Association [5]. This is largely because the data on the
use of ABPM in diabetes, while gradually increasing (includ-
ing in our own studies), currently remains insuﬃcient.2 International Journal of Hypertension
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Figure 1: (a) and (b) represent 24-hour systolic blood pressure (BP), glycosylated hemoglobin (HbA1c), and number of silent cerebral
infarcts (SCIs). (c) and (d) represent 24-hour systolic BP, HbA1c, and left ventricular (LV) mass index (adopted from [8]).
3. Glucose Control and Ambulatory Blood
Pressure Control: Which Is More Important
inPreventingCardiovascularEvents
inDiabeticPatients?
Appropriate blood glucose control is a central part of
the management of diabetes. Tight blood glucose control
can lower not only microvascular complications, but also
the risk of macrovascular disease. A prospective study in
patientswithtype2diabetesreportedanassociationbetween
the degree of hyperglycemia and increased risk of stroke
[6]. However, the United Kingdom Prospective Diabetes
Study (UKPDS) reported that tight control of BP was
more eﬀective than tight control of blood glucose in the
prevention of stroke [7, 8]. Thus there has been some
controversy about whether BP level or glycemic control is
more strongly associated with future cerebrovascular events.
At present, there are few reports comparing the eﬀects of
ambulatory BP and glycemic factors on target organ damage
in diabetic patients. We performed a cross-sectional analysis
to investigate factors associated with target organ damage
(SCI, LVH, and albuminuria) in 244 type 2 diabetics [9].
The mean age was 65.4 years, and the study group included
122 men and 122 women. As shown in Figures 1(a) and
1(b), 24-h systolic BP was signiﬁcantly correlated with the
number of SCIs (r = 0.416, P<. 001), but the average
hemoglobin A1c level was not (r = 0.097, P = .134).
Similarly, as shown in Figures 1(c) and 1(d), 24-h systolic BP
was positively correlated with the LV mass index (r = 0.361,
P<. 001), but the hemoglobin A1c level was not positively
correlated with the LV mass index (r = 0.013, P = .84).
Then the subjects were divided into 4 groups according to
the median values of ambulatory BP and hemoglobin A1c.
AsshowninFigure 2,theprevalenceofSCI,multipleSCIandInternational Journal of Hypertension 3
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Figure 2: (a) Prevalence of hypertensive target organ damage in
each group. SCI = silent cerebral infarct; multiple SCIs = three or
more lesions; LVH = left ventricular hypertrophy; P-values noted
above bars (adopted from [8]). (b) Classiﬁcation of the subjects
based on the median values of ambulatory systolic blood pressure
(SBP) and glycosylated hemoglobin (HbA1c).
LVH were higher in Groups 1 and 3 (with high ambulatory
BP) than in Group 2 (high HbA1c and normal 24-h BP)
or 4 (normal HbA1c and normal 24-h BP). Group 1 had
the highest value of albuminuria among the four groups.
In multiple regression analyses, 24-h systolic BP, age, and
duration of hypertension were signiﬁcantly correlated with
the number of SCIs. On the other hand, 24-h SBP and male
sex were signiﬁcantly correlated with LVMI. We performed
the same analysis for albuminuria, and found that 24-h
systolic BP was most strongly correlated with the presence of
albuminuria. Ambulatory BP control was shown to be more
closely associated with target organ damage of the brain,
heart, and kidney than glycemic control, and it is possible
that ambulatory BP control is eﬀective in preventing future
risk of cardiovascular disease in patients with diabetes.
4. Ambulatory Blood PressureMore
Useful Than Clinic BP for the Management
of DiabeticPatients?
The eﬀectiveness of ABPM in the management of hyper-
tension in diabeticpatients has not been conclusively estab-
lished. Nonetheless, we have shown that ambulatory BP was
superior to clinic BP in predicting cardiovascular prognosis
in patients with diabetes [10]( Figure 3). This ﬁnding was in
agreement with a previous report by Nakano et al. showing
that increased 24-hour pulse pressure was signiﬁcantly
associated with cardiovascular events in diabetes [11]. In
combination with the ﬁndings of masked hypertension in
diabetes (described below) [12], these results lead us to
advocate that all diabetic subjects should undergo ABPM at
least once regardless of the presence of hypertension. Even in
cases of resistant hypertension in diabetes, pseudoresistance,
that is, apparent hypertension in the clinic but normal BP
outside the clinic, is sometimes observed due to the white-
coat eﬀect [13].
5. Is the CircadianBP Rhythm Useful in
PredictingCardiovascularPrognosisin
PatientswithDiabetes?
In diabetes, an abnormal BP rhythm, that is, a non-dipper
pattern, is frequently observed [2]. In patients with diabetes,
nondipping pattern detected by a single ABPM study could
be more reliable than nondiabetic patients as shown by
Cuspidi et al. [14]. There have been several papers on
circadian BP rhythm and CV prognosis in patients with
diabetes. Nakano et al. performed ABPM in 325 patients
with type 2 diabetes who they followed for 4 years to look
at the eﬀect of the riser pattern, an abnormal BP rhythm
in which the average nighttime BP exceeds the average
daytime BP, on future CV events [15]. Circadian BP rhythm
was assessed by the COSINOR (an acronym formed from
cosine and vector) method. A total of 288 patients were
successfully followed, consisting of 201 dippers (N group)
and87risers(Rgroup).Therewerenodiﬀerencesinbaseline
gender, HbA1c, rate of smokers, lipids, or electrolytes,
but the age, rate of hypertension, and rate of diabetic
complications were higher in the R group than in the N
group. During the follow-up period, fatal and nonfatal CV
events (cerebrovascular, cardiovascular, peripheral vascular,
and renovascular) occurred in 20 cases of the N group and
56 cases of the R group. Unadjusted survival and event-free
survival were evaluated by Kaplan-Meier methods, and the
R group had a signiﬁcantly higher number of events than
the N group (Log-rank P<. 001, Figure 4). In multivariable
analyses, after adjusting for various covariates, a riser pattern
andageweresigniﬁcantpredictorsforbothfatalandnonfatal
events. Therefore, in type 2 DM, a riser pattern has been
shown to be associated with fatal and nonfatal vascular
events. In agreement with these results, we found that a riser
pattern was associated with a 150% increase in the risk of
CV disease even after adjusting for other covariates based
on our data of diabetes and CV prognosis [10]. Therefore,
for the prevention of CV disease in the context of diabetes,
physicians should recognize that patients are at high risk
when an abnormal circadian rhythm of BP is observed.
Lurbe et al. studied 75 young patients with type 1
diabetes who had had a normal BP for more than 5 years
and were free from albuminuria at baseline. ABPM was4 International Journal of Hypertension
Table 1: P-values for the comparisons of 4 groups in Figure 6.
SCI Multiple SCI
WCHT versus SHT 0.122 0.010
WCHT versus WCHT + DM 0.160 0.047
WCHT versus SHT + DM <0.001 <0.001
SHT versus WCHT + DM 0.856 1.000
S H Tv e r s u sS H T+D M <0.001 <0.001
W C H T+D Mv e r s u sS H T+D M 0 . 0 0 1 0 . 0 0 1
WCHT = white coat hypertension; SHT = sustained hypertension; WCHT +
DM = white coat hypertension + diabetes mellitus; SHT + DM = sustained
hypertension + diabetes mellitus. P-values for SCI (multiple SCI) were
calculated by chi-square test.
performed at baseline and 2 years later and the status of
albuminuria was assessed [16]. Fourteen patients developed
albuminuria, while the remaining 61 subjects did not. In
the patients who developed albuminuria, nocturnal BP
increased from 109.9 ± 11.3 to 114.9 ± 11.7mmHg (P =
.01), but in patients who did not develop albuminuria,
nocturnal BP did not change (106.0 ± 8.8 versus 106.4 ±
14.8mmHg). The negative predictive value for the progres-
sion for albuminuria was 91% when the night/day ratio
of BP was less than 0.9. Patients with a night/day ratio of
BP ≤ 0.9 showed a 70% reduction of albuminuria (95%
CI 44–110, P = .01, Figure 5) compared to those with a
ratio >0.9. Therefore, even in normotensive diabetes, the
importance of a nondipping pattern was conﬁrmed in this
study.
6. White-CoatHypertensionin Diabetes
The eﬀects of white-coat hypertension in diabetes have not
been fully studied. We performed ABPM and brain MRI
in 360 patients with hypertension, diabetes, or both. SCI,
a risk factor for future stroke, was evaluated by brain MRI
[17]. Among the four groups, SCI was most frequently seen
in diabetic patients with sustained hypertension (deﬁned as
both high clinic BP and high ambulatory BP) and was least
frequently observed in nondiabetic patients with white-coat
hypertension. On the other hand, the frequency of SCI was
similar between nondiabetic patients with sustained HT and
diabetic patients with WCH (Figure 6) Table 1 [18]. White-
coat hypertension has been considered a low-risk factor for
CV events; however, when coexistent with diabetes, white-
coat hypertension does have an impact via so-called white-
coat syndrome [19].
In our follow-up study on the above-described cohort,
the CV prognosis of diabetic WCH was much better than in
the diabetic SHT group (Figure 7)[ 20]. However, because
the number of normotensive diabetics was relatively small,
we could not compare the risk of CV events between
diabetic WCH and diabetic normotensives. On the other
hand, Kramer et al. performed a cross-sectional study which
investigated the eﬀect of white-coat HT in diabetes on the
impact of microvessel disease [21]. They studied 319 type
2 diabetics who were normotensive or who had white-coat
hypertension. Normotension was deﬁned as oﬃce BP <
140/90mmHgandaveragedaytimeBP<135/85mmHg,and
white-coat HT as oﬃce BP ≥ 140/90mmHg and average
daytime BP < 135/85mmHg. Diabetic nephropathy (DN:
deﬁned by 24-hour urinary albumin excretion) and dia-
betic retinopathy (DR: classiﬁcation of the Global Diabetic
Retinopathy Group) were assessed. The results showed that
46 patients with type 2 DM were classiﬁed as having white-
coat hypertension (14.4%), and 117 subjects were deﬁned
as normotensive (36.6%). 24-hour SBP was higher in the
WCH group than in the normotensive group (average 24-
hour BP: 124.7 ± 6.7 versus 121.0 ± 8.5mmHg, P = .01;
average daytime BP: 126.6 ± 7.2 versus 123.2 ± 8.2mmHg,
P = .01). Of note, WCH was associated with the risk of overt
albuminuria (odds ratio: 4.9, 95% CI 1.3–18.7, P = .01). In
the multivariable analysis, WCH was associated with overt
albuminuria (odds ratio: 2.0; 95% CI 1.3–3.2, P = .02) and
nonproliferative and proliferative retinopathy (odds ratio,
2.7, 95% CI 1.2–6.6, P = .02). The authors concluded that
WCH with type 2 DM was associated with an increased
risk of diabetic retinopathy and nephropathy. Therefore,
the combination of WCH and type 2 DM constitutes
some level of risk for CV events and may require some
treatment.
7.Masked HTinDM
Masked hypertension (MHT), a state oﬃce BP is normal
range, but out-of-oﬃce BP is high and has been shown
to be associated with future risk of CV events. However,
the prevalence and clinical signiﬁcance of MHT in patients
with DM have not been fully investigated. We assessed the
association of MHT (deﬁned as a clinic BP < 140/90mmHg
and daytime ambulatory BP > 135/85mmHg) with micro-
and macrovascular end organ damage in 81 clinically
normotensive Japanese diabetics [12]. The prevalence of
SCI and albuminuria was evaluated, and the left ventricular
mass (LVM) was determined. Among the 81 patients, the 38
(46.9%) who were classiﬁed as having MHT showed signiﬁ-
cantly more SCIs (mean ± SEM: 2.5 ± 0.5v e r s u s1 .1 ± 0.2,
P = .017), and signiﬁcantly higher incidence of albuminuria
(39% versus 16%, P = .025), but no increase of LVMI
compared to the true normotensive group. We concluded
that the prevalence of MHT in this diabetic population was
47%, a surprisingly high result. Diabetic patients with MHT
showed evidence of brain and kidney damage. Leit˜ ao et al.
performed a similar study in 135 normotensive patients with
type 2 diabetes [22]. Patients underwent urinary albumin
excretion rate (UAER) measurement, echocardiography, and
24-h ambulatory blood pressure monitoring (ABPM). The
deﬁnition of masked hypertension was the same as in our
study. The prevalence of masked hypertension was 30%
(n = 41). UAER and LV wall thickness were signiﬁcantly
higher in the group with masked hypertension than in the
normotensives. After adjustments for covariates, all associa-
tions were sustained for daytime systolic blood pressure but
not for oﬃce systolic blood pressure. Hence out-of-oﬃce
monitoring of BP may be indicated even in diabetics whose
BPs are normal in the clinic.International Journal of Hypertension 5
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Figure 3: Event-free survival Kaplan-Meier curves for three categories of awake and sleep SBP. The log-rank statistic between the highest-
and lowest-awake SBP is 11.2 (P = .001) for the diabetes and 8.4 (P = .004) for the non-diabetes group, while that between the middle- and
lowest-awake SBP is 4.5 (P = .03) for the diabetes and 1.0 (P = .32) for the non-diabetes group. The log-rank statistic between the highest-
and middle-awake SBP is 1.8 (P = .19) for the diabetes and 4.0 (P = .046) for the non-diabetes group. The log-rank statistic between the
highest- and lowest-sleep SBP is 16.3 (P<. 001) for the diabetes and 11.3 (P = .001) for the non-diabetes group, and that between the
middle- and lowest-sleep SBP is 3.3 (P = .07) for the diabetes and 3.8 (P = .05) for the non-diabetes group. The log-rank statistic between
the highest- and lowest-sleep SBP is 6.4 (P = .01) for the diabetes and 1.9 (P = .17) for the non-diabetes group. SBP indicates systolic blood
pressure (adopted from [10]).
8. Ambulatory Blood Pressure
Monitoringinthe Obese
There has been conﬂicting evidence that obesity or over-
weight is associated with abnormal circadian rhythm of BP.
Kotsis et al. demonstrated that normal nocturnal BP reduc-
tion was signiﬁcantly decreased from normal weight to obese
in 3,216 untreated hypertensive patients. The prevalence of
nondipperswasmuchgreaterintheobesethaninthenormal
weight group (71.4% versus 41.1% in the normotensive and
72.7% versus 61.5% in the hypertensive subsets) [23]. In
the Oman Family Study (n = 1,124), BMI was reported to
be signiﬁcantly associated with a nocturnal dipping pattern
(r =− 0.23) in a multivariate model among patients with
metabolic syndrome [24]. In a data from the Spanish Society
ofHypertensionregistry,obesitywasoneofthedeterminants
of non-dipper pattern [2]. In contrast, Diamantopoulos
et al. examined 226 (116 male and 110 female) overweight6 International Journal of Hypertension
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Figure 4: Survival curves (a) and event-free survival curves (b) of diabetic subjects with normal (N) and reversed circadian BP rhythm. The
unadjusted relative risk for diabetic subjects with a reversed circadian BP rhythm was 20.6-fold higher than that of subjects with a normal
rhythm (P<. 001; Cox-Mantel’s test) for survival curves (a), and 12.9-fold higher than that of subjects with a normal rhythm (P<. 001;
Cox-Mantel’s test) for event-free survival curves (b) (adopted from [11]).
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and obese subjects (BMI > 27kg/m2) with newly diagnosed
essential hypertension. There were no signiﬁcant diﬀerences
inBMIbetweenthedippersandnondippers[25].Obesemen
had an increased heart rate and diastolic BP compared to
normal and overweight men, but those were similar between
the normal and obese women [26]. Such a gender diﬀerence
could reﬂect some pathophysiological mechanism of BP and
obese status. Because obesity is associated with many other
factors, such as diabetes, Metabolic Syndrome (MS), and
Sleep apnea syndrome, it is diﬃcult to isolate any single
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component in human studies. Further studies will be needed
to examine the relationship between obesity and dipping
patterns.
9. Metabolic Syndrome and
CircadianRhythmof BP
There has been accumulating evidence that metabolic syn-
drome is associated with nondipping of BP. Hermida et al.
studied 1770 nondiabetic untreated hypertensive patients,
andperformedABPMfor48hours[27].Theyfoundthatthe
prevalenceofanondippingproﬁlewassigniﬁcantlyhigherin
patients with MS (46.1% versus 37.5% in patients without
MS, P<. 001). The single most relevant factor in theInternational Journal of Hypertension 7
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group was not signiﬁcantly diﬀerent from that in the WCH group
(χ2 = 2.2, P = .14). SH, sustained hypertension; WCH, white-coat
hypertension (Adopted from [20]).
deﬁnition of MS associated with nondipping was elevated
waist circumference. There are other reports supporting the
relationship between MS and a nondipping pattern [24,
28–30]. Additionally, nondipping status has been shown
to be an independent predictor of glucose tolerance and
severalothermetabolicabnormalities[31].Incontrast,other
studies reported no diﬀerence in the ambulatory BP patterns
between patients with and those without MS. With regard to
the components of MS, glucose and abdominal obesity were
two important components, but the number of components
itself was also a determinant of the nondipping pattern.
The common pathological states between MS and the
nondipping status would be hyperinsulinemia and resultant
sympathetic hyperactivity. However, it is not clear which
component is the most important factor in determining
nondippingstatusintheMS,becausemanyfactorswhichare
related to nondipping patterns, such as abdominal obesity,
diabetes, and sleep apnea syndrome, coexist in the same
individuals. Further studies will be needed to clarify the
relationship between MS and the nondipping pattern.
10. Conclusion
In patients with diabetes and obesity, ABPM should be
performed at least once for the better risk stratiﬁcation of
hypertension. Early detection of nocturnal hypertension (in
its most extreme form, a “riser pattern”) is very important
for preventing cardiovascular events. ABPM data are also
eﬀective to improve adherence to therapy. Further studies
will be needed for the proper application of ABPM in such
high-risk populations.
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